Number: 201102462 Principal Investigator: Lockhart, A. Craig
Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies
Phase: I Disease Site: Multiple Sites
Participating Site(s):
Main Campus
Map and Directions
Contact: 800-600-3606 or

The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This study will be the first time ZSTK474
is given to humans. The FDA is allowing ZSTK474 to be used in research studies like this one in a limited number of people.
ZSTK474 is a drug which attaches to specific spots on cancer cells. It is thought that by attaching itself to those spots, it may be able to prevent cancer cells from multiplying, thus preventing tumors from growing.
More Information: Entry
Internal Protocol Documents (requires Siteman administrative database password)